CDW's (SGX:BXE) subsidiary, A Biotech's joint research with Neoregen for next-generation Lipid Nanoparticle (LNP) technology, reached the in vivo phase after positive results from the in vitro research phase, according to a filing with the Singapore Exchange on Tuesday.
The research is aimed at the development of mRNA vaccines and other treatments that can be used in cancer treatment and gene therapy.
The latest phase is expected to last around one year, and if successful, will allow CDW and Neoregen to license out the technology and enter into licensing negotiations with pharmaceutical companies.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。